ArticleDiscover oncology2026
Molecular international prognostic index prognostic model in diffuse large B-cell lymphoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough diffuse large B-cell lymphoma (DLBCL) has entered the era of molecular subtyping, gene mutations have not yet been used for risk stratification of patients with DLBCL. Therefore, there is an urgent need for a molecular-based model to comprehensively evaluate the prognosis of DLBCL patients in clinical practice.
methodsWe retrospectively analyzed 761 patients with DLBCL from cBioPortal datasets. Gene mutations and the International Prognostic Index (IPI) were analyzed for their associations with overall survival and were used to determine the set of prognostic variables. A Cox model was utilized to estimate the relative weights of the selected variables.
resultsWe mapped at least one gene mutation in 94% (718/761) of patients with DLBCL. Survival analysis identified that PIM1, KLHL14, CD79b, and MYC mutations were correlated with adverse outcomes, whereas EZH2, STAT3, and B2M mutations were predictors of favorable outcomes. Using these gene mutations together with IPI, we established a novel prognostic system, IPI-M, which resulted in a unique risk score for individual patients. We further derived five IPI-M risk categories (very low, low, intermediate, high, and very high), demonstrating stronger prognostic separation in DLBCL. Compared with IPI, the discrimination ability of IPI-M showed a better discrimination of survival with concordance index value and higher 1-year, 3-year, and 5-year survival as measured by area under the receiver operating characteristic curve values. Finally, IPI-M model also presented a prognostic separation for overall survival especially for the discrimination of high/very high patients from intermediate/low/very low patients in an external validation cohort.
conclusionsWe developed a novel, feasible integrated prognostic system for newly diagnosed DLBCL that incorporates the IPI and genetic mutations, which facilitates precise prognostic assessment in clinical practice and supports precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.